# EDGAR Filing Document

**Accession Number:** 0001348911
**File Stem:** 0001193125-26-267548
**Filing Date:** 2026-6
**Character Count:** 15829
**Document Hash:** 7f4c31dc095362ba33c925398f9379df
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-267548.hdr.sgml**: 20260611

**ACCESSION NUMBER**: 0001193125-26-267548

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260611

**DATE AS OF CHANGE**: 20260611

**EFFECTIVENESS DATE**: 20260611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KalVista Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001348911
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 200915291
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-216032
- **FILM NUMBER:** 261083151

**BUSINESS ADDRESS:**
- **STREET 1:** 200 CROSSING BOULEVARD
- **CITY:** FRAMINGHAM
- **STATE:** MA
- **ZIP:** 01702
- **BUSINESS PHONE:** (857) 999-0075

**MAIL ADDRESS:**
- **STREET 1:** 200 CROSSING BOULEVARD
- **CITY:** FRAMINGHAM
- **STATE:** MA
- **ZIP:** 01702

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Carbylan Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20140916

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Carbylan Biosurgery, Inc
- **DATE OF NAME CHANGE:** 20130102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Carbylan Biosurgery Inc
- **DATE OF NAME CHANGE:** 20060105

**As filed with the Securities and Exchange Commission on June 11, 2026** 

**Registration No. 333-203721** 

**Registration No. 333-215184** 

**Registration No. 333-216032** 

**Registration No. 333-217008** 

**Registration No. 333-226442** 

**Registration No. 333-230279** 

**Registration No. 333-237059** 

**Registration No. 333-254178** 

**Registration No. 333-257871** 

**Registration No. 333-263431** 

**Registration No. 333-269174** 

**Registration No. 333-272777** 

**Registration No. 333-276444** 

**Registration No. 333-280579** 

**Registration No. 333-284321** 

**Registration No. 333-292960** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-203721** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-215184** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-216032** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-217008** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-226442** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230279** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237059** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-254178** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-257871** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263431** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-269174** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-272777** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-276444** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-280579** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-284321** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-292960** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## KALVISTA PHARMACEUTICALS, INC.
**(Exact Name of Registrant as Specified in Its Charter)** 

---

| | |
|:---|:---|
| **Delaware** | **20-0915291** |
| **(State or Other Jurisdiction of**<br> **Incorporation or Organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**KalVista Pharmaceuticals, Inc.** 

**200 Crossing Boulevard** 

**Framingham, MA 01702** 

**(Address of Principal Executive Offices) (Zip Code)** 

**Amended and Restated 2004 Stock Option Plan** 

**2014 Stock Option Plan** 

**2015 Incentive Plan** 

**Options to purchase stock granted under the KalVista Pharmaceuticals Ltd Enterprise Management** 

**Incentive Scheme and assumed by the Registrant** 

**Non-Plan Inducement Options** 

**2017 Equity Incentive Plan** 

**2017 Employee Stock Purchase Plan** 

**Amended and Restated 2021 Equity Inducement Plan** 

**(Full Title of the Plans)** 

**John Hess** 

**Chairman of the Board; President; General Manager** 

**KalVista Pharmaceuticals, Inc.** 

**One Boston Place, Suite 4000** 

**Boston, Massachusetts 02108** 

**(Name and Address of Agent For Service)** 

**(888) 466-6505** 

**(Telephone Number, including area code, of agent for service)** 

***Copies to:***

**Zachary Blume** 

**Ropes & Gray LLP** 

**800 Boylston Street, Prudential Tower** 

**Boston, MA 02199** 

**Telephone: (617) 951-7000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**DEREGISTRATION OF SECURITIES** 

These Post-Effective Amendments (these "Post-Effective Amendments") filed by KalVista Pharmaceuticals, Inc. ("KalVista" or the "Registrant") relate to the following registration statements on Form S-8 (together, the "Registration Statements"):

1. [Registration Statement No. 333-203721](http://www.sec.gov/Archives/edgar/data/1348911/000119312515155836/d913984ds8.htm) , registering an aggregate of 2,467,625 shares of common stock of Carbylan Therapeutics, Inc., issuable under the Amended and Restated 2004 Stock Option Plan, as amended, the
2014 Stock Option Plan and the 2015 Incentive Plan, which was filed with the U.S. Securities and Exchange Commission (the "SEC") on April 29, 2015.

2. [Registration Statement No. 333-215184](http://www.sec.gov/Archives/edgar/data/1348911/000119312516797802/d311092ds8.htm) , registering (i) an aggregate of 212,162 shares of KalVista's common stock, $0.001 par value per share (the "Common Stock") subject to issuance by
KalVista upon the exercise of options granted under the Enterprise Management Incentive Scheme of KalVista Pharmaceuticals Ltd., a private company limited by shares incorporated and registered in England and Wales ("KalVista Ltd."), and
converted into options assumed by KalVista in accordance with the terms of a Share Purchase Agreement dated as of June 15, 2016, by and among KalVista, KalVista Ltd., the shareholders of KalVista Ltd. and the Seller Representative (as defined
therein) and (ii) an aggregate of 20,055 shares of the Common Stock reserved for issuance upon the exercise of a non-plan inducement stock option grant, which was filed with the SEC on December 20,
2016. 3. [Registration Statement No. 333-216032](http://www.sec.gov/Archives/edgar/data/1348911/000119312517040397/d318794ds8.htm) , registering an aggregate of 85,714 shares of Common Stock reserved for issuance under the 2015 Incentive Plan, which was filed with the SEC on February 13, 2017.

4. [<u>Registration Statement No.</u> <u>333-217008</u>](http://www.sec.gov/Archives/edgar/data/1348911/000119312517101768/d359567ds8.htm) , registering an aggregate of 1,449,702 shares of Common Stock, consisting of (i) 65,000 shares of Common Stock reserved for issuance upon the exercise of a non-plan inducement stock option grant, (ii) 1,284,702 shares of Common Stock reserved for issuance under the 2017 Equity Incentive Plan (the "2017 Plan") and (iii) 100,000 shares of Common Stock
reserved for issuance under the 2017 Employee Stock Purchase Plan (the "2017 ESPP"), which was filed with the SEC on March 29, 2017;

5. [<u>Registration Statement No.</u> <u>333-226442</u>](http://www.sec.gov/Archives/edgar/data/1348911/000156459018017916/kalv-s8.htm) , registering an aggregate of 431,706 shares of Common Stock reserved for issuance under the 2017 Plan, which was filed with the SEC on July 30, 2018;

6. [<u>Registration Statement No.</u> <u>333-230279</u>](http://www.sec.gov/Archives/edgar/data/1348911/000156459019007847/kalv-s8.htm) , registering an aggregate of 689,563 shares of Common Stock reserved for issuance under the 2017 Plan, which was filed with the SEC on March 14, 2019;

7. [<u>Registration Statement No.</u> <u>333-237059</u>](http://www.sec.gov/Archives/edgar/data/1348911/000156459020009778/kalv-s8.htm) , registering an aggregate of 892,129 shares of Common Stock, consisting of (i) 713,704 shares of Common Stock reserved for issuance under the 2017 Plan and (ii)
178,425 shares of Common Stock reserved for issuance under the 2017 ESPP, which was filed with the SEC on March 10, 2020;

8. [<u>Registration Statement No.</u> <u>333-254178</u>](http://www.sec.gov/Archives/edgar/data/1348911/000119312521077974/d25428ds8.htm) , registering an aggregate of 898,896 shares of Common Stock, consisting of (i) 719,117 shares of Common Stock reserved for issuance under the 2017 Plan and (ii)
179,779 shares of Common Stock reserved for issuance under the 2017 ESPP, which was filed with the SEC on March 11, 2021;

9. [<u>Registration Statement No.</u> <u>333-257871</u>](http://www.sec.gov/Archives/edgar/data/1348911/000156459021036474/kalv-s8.htm) , registering an aggregate of 350,000 shares of Common Stock reserved for issuance under the 2021 Equity Inducement Plan (as amended, the "2021 Plan"),
which was filed with the SEC on July 13, 2021;

10. [<u>Registration Statement No.</u> <u>333-263431</u>](http://www.sec.gov/Archives/edgar/data/1348911/000095012322003398/s-8_q3_fy22.htm) , registering an aggregate of 1,223,496 shares of Common Stock, consisting of (i) 978,797 shares of Common Stock reserved for issuance under the 2017 Plan and (ii)
244,699 shares of Common Stock reserved for issuance under the 2017 ESPP, which was filed with the SEC on March 10, 2022;

------

11. [<u>Registration Statement No.</u> <u>333-269174</u>](http://www.sec.gov/Archives/edgar/data/1348911/000095017023000615/2023_s-8.htm) , registering an aggregate of 1,705,117 shares of Common Stock, consisting of (i) 1,364,094 shares of Common Stock reserved for issuance under the 2017 Plan and (ii)
341,023 shares of Common Stock reserved for issuance under the 2017 ESPP, which was filed with the SEC on January 10, 2023;

12. [<u>Registration Statement No.</u> <u>333-272777</u>](http://www.sec.gov/Archives/edgar/data/1348911/000095017023028927/june_2023_s-8_kalv.htm) , registering an aggregate of 500,000 shares of Common Stock reserved for issuance under the 2021 Plan, which was filed with the SEC on June 20, 2023;

13. [<u>Registration Statement No.</u> <u>333-276444</u>](http://www.sec.gov/Archives/edgar/data/1348911/000095017024003362/2024_s-8.htm) , registering an aggregate of 1,727,935 shares of Common Stock, consisting of (i) 1,382,348 shares of Common Stock reserved for issuance under the 2017 Plan and (ii)
345,587 shares of Common Stock reserved for issuance under the 2017 ESPP, which was filed with the SEC on January 9, 2024;

14. [<u>Registration Statement No.</u> <u>333-280579</u>](http://www.sec.gov/Archives/edgar/data/1348911/000095017024079078/june_2024_s-8_kalv.htm) , registering an aggregate of 600,000 shares of Common Stock reserved for issuance under the 2021 Plan, which was filed with the SEC on June 28, 2024;

15. [<u>Registration Statement No.</u> <u>333-284321</u>](http://www.sec.gov/Archives/edgar/data/1348911/000095017025006240/jan_2025_s-8.htm) , registering an aggregate of 2,971,680 shares of Common Stock, consisting of (i) 1,977,344 shares of Common Stock available for issuance under the 2017 Plan, (ii)
494,336 shares of Common Stock available for issuance under the 2017 ESPP and (iii) 500,000 shares of Common Stock available for issuance under the 2021 Plan, which was filed with the SEC on January 16, 2025; and

16. [<u>Registration Statement No.</u> <u>333-292960</u>](http://www.sec.gov/Archives/edgar/data/1348911/000119312526022749/d63436ds8.htm) , registering an aggregate of 2,945,038 shares of Common Stock, consisting of (i) 2,036,031 shares of Common Stock available for issuance under the 2017 Plan, (ii)
509,007 shares of Common Stock available for issuance under the 2017 ESPP and (iii) 400,000 shares of Common Stock available for issuance under the 2021 Plan, which was filed with the SEC on January 26, 2026.

On April 29, 2026, KalVista entered into a Merger Agreement with Chiesi Farmaceutici S.p.A., an Italian *società per azioni* ("Chiesi"), Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Chiesi ("Purchaser"), and KalVista Pharmaceuticals Limited, a private limited company organized under the laws of England and Wales (the "Merger Agreement").

On June 11, 2026, KalVista completed its merger with Purchaser pursuant to the Merger Agreement, whereby Purchaser merged with and into KalVista (the "Merger"), in accordance with the General Corporation Law of the State of Delaware, with KalVista continuing as the surviving corporation and as a wholly owned subsidiary of Chiesi. As a result of the Merger, KalVista has terminated any and all offerings of its securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements.

In accordance with undertakings made by KalVista in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance under the Registration Statements that remain unsold at the termination of the offerings, KalVista hereby removes from registration all such securities registered pursuant to the Registration Statements that remain unsold or otherwise unissued as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities, and KalVista hereby terminates the effectiveness of the Registration Statements. After giving effect to these Post-Effective Amendments, there will be no remaining securities registered by KalVista pursuant to the Registration Statements.

The foregoing description of the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Merger Agreement, which is attached as Exhibit 2.1 to KalVista's Current Report on Form 8-K filed with the SEC on April 29, 2026.

------

**SIGNATURE** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on June 11, 2026.

---

| | |
|:---|:---|
| **KALVISTA PHARMACEUTICALS, INC.** | **KALVISTA PHARMACEUTICALS, INC.** |
| By: | /s/ John Hess |
| Name: | John Hess |
| Title: | Chairman of the Board; President;<br> General Manager |

---

No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.